Natera, Inc. $NTRA Holdings Boosted by Asset Management One Co. Ltd.

Key Points

• Asset Management One increased its Natera stake by 6.8% in the third quarter to 51,919 shares valued at approximately $21.5 million. Institutional investors collectively own 99.9% of Natera’s outstanding stock.
• Natera’s latest quarterly results exceeded expectations, with revenue rising 37.7% year over year to $752.8 million and an adjusted loss of $0.47 per share versus the $0.49 consensus loss.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and average price target of $394.31, although the stock’s sharp rise, insider selling and potential negative earnings outlook could increase volatility.

Asset Management One Co. Ltd. boosted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 6.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 51,919 shares of the medical research company's stock after purchasing an additional 3,293 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Natera were worth $21,459,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SYM FINANCIAL Corp raised its holdings in shares of Natera by 1.7% in the 3rd quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company's stock worth $784,000 after acquiring an additional 32 shares during the last quarter. Versant Capital Management Inc lifted its position in Natera by 4.6% in the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company's stock valued at $337,000 after acquiring an additional 36 shares in the last quarter. Parallel Advisors LLC lifted its position in Natera by 5.5% in the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock valued at $181,000 after acquiring an additional 47 shares in the last quarter. Raiffeisen Bank International AG boosted its stake in Natera by 48.5% during the 2nd quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company's stock valued at $41,000 after purchasing an additional 49 shares during the last quarter. Finally, First Horizon Corp boosted its stake in Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company's stock valued at $196,000 after purchasing an additional 51 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Activity

In other news, insider John Fesko sold 898 shares of the company's stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total value of $382,853.32. Following the transaction, the insider owned 195,578 shares of the company's stock, valued at approximately $83,382,724.52. This represents a 0.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,430 shares of Natera stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total value of $1,462,346.20. Following the sale, the chief executive officer owned 91,232 shares of the company's stock, valued at approximately $38,895,850.88. This trade represents a 3.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 49,748 shares of company stock worth $17,162,006. Insiders own 5.05% of the company's stock.

Natera Stock Performance

Shares of NTRA opened at $436.00 on Friday. The stock's fifty day moving average price is $375.27 and its two-hundred day moving average price is $265.54. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company's revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.74) earnings per share. As a group, analysts forecast that Natera, Inc. will post -1.14 EPS for the current year.

Analysts Set New Price Targets

NTRA has been the subject of several recent research reports. BTIG Research upped their price target on Natera from $320.00 to $430.00 and gave the stock a "buy" rating in a report on Tuesday. Stephens raised their price objective on Natera from $305.00 to $350.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Evercore restated an "outperform" rating and set a $300.00 price objective on shares of Natera in a research note on Monday, July 6th. Piper Sandler lifted their price objective on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. Finally, Wells Fargo & Company upped their target price on shares of Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $394.31.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Natera Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.